Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Sleep  COVID-19 treatment studies for Sleep  C19 studies: Sleep  Sleep   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 43% Improvement Relative Risk Hospitalization 36% Hospitalization (b) 21% c19early.com/sl Li et al. Sleep for COVID-19 Prophylaxis Favors good sleep Favors control
Li, 46,535 patient sleep study: 43% lower mortality [p=0.02] and 36% lower hospitalization [p=0.008] https://c19p.org/li13
copied to clipboard
Poor sleep behavior burden and risk of COVID-19 mortality and hospitalization
Li et al., Sleep, doi:10.1093/sleep/zsab138
18 Jun 2021    Source   PDF   Share   Tweet
UK Biobank retrospective, 46,535 participants with sleep behavior assessed between 2006 and 2010, showing higher risk of hospitalization and mortality with poor sleep.
risk of death, 43.2% lower, OR 0.57, p = 0.02, fully adjusted model C, significant poor sleep burden, RR approximated with OR.
risk of hospitalization, 35.9% lower, OR 0.64, p = 0.008, fully adjusted model C, significant poor sleep burden, RR approximated with OR.
risk of hospitalization, 21.3% lower, OR 0.79, p = 0.02, fully adjusted model C, moderate poor sleep burden, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 6/18/2021, retrospective, USA, North America, peer-reviewed, mean age 69.4, 8 authors, study period March 2020 - December 2020.
Contact: pli9@bwh.harvard.edu, khu1@bwh.harvard.edu, lgao@mgh.harvard.edu.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit